JPMorgan Chase & Co. Cuts Stryker (NYSE:SYK) Price Target to $400.00

Stryker (NYSE:SYK) had its target price cut by research analysts at JPMorgan Chase & Co. from $445.00 to $400.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 33.34% from the stock’s previous close.

A number of other research firms have also weighed in on SYK. Needham & Company LLC cut their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday. Barclays reaffirmed an “overweight” rating and issued a $469.00 price target on shares of Stryker in a report on Monday, February 2nd. The Goldman Sachs Group reduced their price objective on Stryker from $403.00 to $357.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Evercore set a $355.00 price objective on Stryker in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a report on Friday. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $403.90.

Stryker Stock Performance

Stryker stock traded down $15.15 during trading hours on Friday, hitting $299.98. 2,757,523 shares of the stock traded hands, compared to its average volume of 2,066,263. The firm’s 50 day moving average price is $345.67 and its 200-day moving average price is $356.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The stock has a market capitalization of $114.89 billion, a price-to-earnings ratio of 35.71, a P/E/G ratio of 1.84 and a beta of 0.92. Stryker has a 1 year low of $299.14 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the firm earned $2.84 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker will post 14.91 EPS for the current fiscal year.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stryker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. Czech National Bank boosted its holdings in shares of Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after purchasing an additional 3,366 shares during the last quarter. Davis R M Inc. increased its holdings in shares of Stryker by 1.8% during the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after buying an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC purchased a new position in shares of Stryker in the 3rd quarter worth $1,216,000. Kepler Cheuvreux Suisse SA acquired a new position in Stryker in the third quarter valued at $27,952,000. Finally, Daymark Wealth Partners LLC grew its position in Stryker by 436.0% during the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after acquiring an additional 37,307 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook of roughly 8%–9.5% organic sales growth and adjusted EPS guidance of $14.90–$15.10, signaling management confidence in recovery from the cyber incident. Stryker maintains 2026 outlook
• Positive Sentiment: Operational cash flow and net income improved materially in Q1 (cash from operations jumped and net income rose year‑over‑year), which supports the balance sheet and longer‑term investment capacity. Q1 results: cash flow & net income up
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference (May 13), giving investors a near‑term forum for management Q&A and clearer color on cyber recovery and growth drivers. Stryker to participate in BofA conference
• Neutral Sentiment: Several sell‑side firms cut price targets (e.g., Wells Fargo, Needham, BTIG, Truist trimmed targets) but many preserved buy/overweight ratings — that reduces near‑term upside expectations while leaving medium‑term analyst support intact. Analyst price target changes
• Negative Sentiment: Q1 adjusted EPS ($2.60) and revenue ($6.02B) missed consensus, with management attributing shortfalls to a cyber incident that disrupted production, dented margins and slowed growth across key segments. That is the primary driver of the stock weakness today. Stryker Q1 earnings & sales miss on cyber disruption
• Negative Sentiment: News and coverage highlight softer demand in some product lines (spinal/orthopaedics) and margin contraction on an adjusted basis, raising near‑term growth concerns. Reuters: Stryker misses estimates on muted demand
• Negative Sentiment: Large insider and institutional selling activity noted in data aggregators may increase investor caution and amplify short‑term selling pressure. Insider & institutional activity

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.